德国新诊断胶质母细胞瘤长期使用替莫唑胺治疗的成本效益
该研究构建马尔可夫模型,比较新诊断胶质母细胞瘤患者长期使用替莫唑胺(至疾病进展)与标准治疗(同步放化疗后六个周期替莫唑胺)在60个月时间范围内的医疗费用与临床结局。长期治疗组中位总生存期17.1个月,中位无进展生存期7.4个月;增量效果为0.022质量调整生命年(QALYs),增量成本效果比(ICER)为351,909欧元/QALY。敏感性分析显示,对ICER影响最大的参数是两治疗组中疾病进展状态的健康效用值。
要点
- 长期替莫唑胺治疗组中位总生存期17.1个月,中位无进展生存期7.4个月。
- 基础病例分析中,长期替莫唑胺治疗的ICER为351,909欧元/QALY。
- 对ICER影响最大的参数是两治疗组中疾病进展状态的健康效用值。
核心结论
- 尽管长期替莫唑胺治疗非常昂贵,其ICER与新诊断胶质母细胞瘤标准替莫唑胺治疗相当。
研究设计与样本
- 构建马尔可夫模型,比较长期替莫唑胺治疗与标准治疗在60个月时间范围内的医疗费用和临床结局。
- 标准治疗组的转移概率根据Stupp等人的随机对照试验数据计算。
- 长期替莫唑胺治疗数据通过匹配耶拿大学医院神经外科治疗的一个队列收集。
- 成本视角基于医疗保险。
主要发现
- 基础病例分析显示,长期替莫唑胺治疗组中位总生存期为17.1个月,中位无进展生存期为7.4个月。
- 使用所有基础病例参数的时间依赖马尔可夫模型进行成本效果分析,增量效果为0.022质量调整生命年(QALYs)。
- 增量成本效果比(ICER)为351,909欧元/QALY。
- 敏感性分析显示,对ICER影响最大的参数是两治疗组中疾病进展状态的健康效用值。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Concomitant radiochemotherapy followed by six cycles of temozolomide (= short term) is considered as standard therapy for adults with newly diagnosed glioblastoma. In contrast, open-end administration of temozolomide until progression (= long-term) is proposed by some authors as a viable alternative. We aimed to determine the cost-effectiveness of long-term temozolomide therapy for patients newly diagnosed with glioblastoma compared to standard therapy. A Markov model was constructed to compare medical costs and clinical outcomes for both therapy types over a time horizon of 60 months. Transition probabilities for standard therapy were calculated from randomized controlled trial data by Stupp et al. The data for long-term temozolomide therapy was collected by matching a cohort treated in the Department of Neurosurgery at Jena University Hospital. Health utilities were obtained from a previous cost utility study. The cost perspective was based on health insurance. The base case analysis showed a median overall survival of 17.1 months and a median progression-free survival of 7.4 months for patients in the long-term temozolomide therapy arm. The cost-effectiveness analysis using all base case parameters in a time-dependent Markov model resulted in an incremental effectiveness of 0.022 quality-adjusted life-years (QALYs). The incremental cost-effectiveness ratio (ICER) was €351,909/QALY. Sensitivity analyses showed that parameters with the most influence on ICER were the health state utility of progression in both therapy arms. Although open-ended temozolomide therapy is very expensive, the ICER of this therapy is comparable to that of the standard temozolomide therapy for patients newly diagnosed with glioblastoma.
引用
- Waschke A, Arefian H, Walter J, et al. Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany. J Neurooncol. 2018. PMID: 29468446. doi:10.1007/s11060-018-2804-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。